BioNTech SE logo
BioNTech SE BNTX
$ 102.17 2.32%

Annual report 2024
added 01-10-2026

report update icon

BioNTech SE EPS Ratio 2011-2026 | BNTX

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio BioNTech SE

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - 42.2 0.06 -0.85 -0.25 -0.51 - - - - - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
42.2 -0.85 8.13

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-15.4 - 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
-13.7 - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-24.9 - - $ 1.01 B usaUSA
Adagene Adagene
ADAG
-0.59 $ 1.65 7.91 % $ 92.9 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-0.53 $ 3.59 1.99 % $ 8.64 B australiaAustralia
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
-0.01 $ 66.05 2.3 % $ 8.83 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-0.86 $ 1.52 -16.3 % $ 388 M britainBritain
Biophytis SA Biophytis SA
BPTS
-0.26 - -13.47 % $ 169 M franceFrance
Akero Therapeutics Akero Therapeutics
AKRO
-3.75 - - $ 3.67 B usaUSA
Biogen Biogen
BIIB
11.2 $ 184.48 -1.67 % $ 26.9 B usaUSA
AVROBIO AVROBIO
AVRO
0.27 - 1083.1 % $ 745 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-31 - -18.52 % $ 27.3 M britainBritain
AstraZeneca PLC AstraZeneca PLC
AZN
0.08 $ 93.52 -1.2 % $ 96.9 B britainBritain
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-0.01 $ 4.25 1.67 % $ 9.25 B israelIsrael
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-0.47 - 0.49 % $ 251 B cayman-islandsCayman-islands
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
-0.81 - -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
-1.42 - -7.31 % $ 87 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
-4.41 $ 55.71 -0.28 % $ 113 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-8.28 $ 207.49 2.22 % $ 5 B danmarkDanmark
Codiak BioSciences Codiak BioSciences
CDAK
-1.7 - -55.98 % $ 2.15 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
-3.87 - 1052.0 % $ 415 M usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
-2.67 - - $ 7.29 B usaUSA
Acasti Pharma Acasti Pharma
ACST
-0.79 - 4.01 % $ 150 M canadaCanada
Zai Lab Limited Zai Lab Limited
ZLAB
-0.26 $ 18.37 -0.97 % $ 18.2 B chinaChina
Coherus BioSciences Coherus BioSciences
CHRS
-2.53 $ 1.61 -5.03 % $ 152 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
-1.41 $ 10.84 0.46 % $ 714 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
-2.4 - -16.75 % $ 25.8 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
-2.45 $ 25.59 -6.54 % $ 1.65 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
-2.55 $ 4.22 -4.2 % $ 116 M franceFrance
Clearside Biomedical Clearside Biomedical
CLSD
-0.53 - - $ 25.3 M usaUSA
Chimerix Chimerix
CMRX
-0.93 - - $ 756 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
-0.09 - -15.15 % $ 60.3 M britainBritain
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
1.35 $ 37.35 -0.4 % $ 3.86 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
1.38 $ 23.18 2.02 % $ 2.75 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
-2.38 - 1.93 % $ 17.4 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-1.77 - -0.23 % $ 916 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-2.21 - - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
-1.66 - 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-1.73 - - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
-11.7 - 4.14 % $ 49.1 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
-3.69 $ 55.11 3.49 % $ 4.45 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
-4.34 $ 55.17 2.47 % $ 4.65 B schweizSchweiz
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-2.46 - - $ 7.46 M israelIsrael
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
-4.47 $ 3.53 -5.75 % $ 231 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-10.7 - -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
3.29 $ 29.43 6.09 % $ 1.43 B usaUSA